Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10375404" target="_blank" >RIV/00216208:11130/18:10375404 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/18:10375404 RIV/00209805:_____/18:00078107
Result on the web
<a href="https://doi.org/10.1016/j.jgo.2017.07.010" target="_blank" >https://doi.org/10.1016/j.jgo.2017.07.010</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.jgo.2017.07.010" target="_blank" >10.1016/j.jgo.2017.07.010</a>
Alternative languages
Result language
angličtina
Original language name
Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial
Original language description
Objectives: Aflibercept (ziv-aflibercept) significantly improves progression-free (PFS) and overall survival (OS) when added to 5-fluorouracil, leucovorin and irinotecan (FOLFIRI), compared with FOLFIRI alone, in patients with metastatic colorectal cancer previously treated with oxaliplatin-based therapy. This subset analysis of the VELOUR study investigates aflibercept plus FOLFIRI versus placebo plus FOLFIRI according to age. Methods: Efficacy and safety were analyzed by treatment arm and age (>= or <65 years). Results: Overall, 443 patients were 65 years old (205 in aflibercept arm; 238 in placebo arm) and 783 were <65 years old (407 in aflibercept arm; 376 in placebo arm). Median OS was 12.6 versus 11.3 months (hazard ratio [HR]: 0.85; 95.34% CI 0.68-1.07) in patients >= 65 years old and 14.5 versus 12.5 months (HR: 0.80; 95.34% CI 0.67-0.95) in those patients <65 years old, for patients receiving FOLFIRI plus aflibercept or placebo, respectively. There was no interaction between treatment and age. Treatment-emergent adverse events (AEs) were comparable for patients <65 years and >= 65 years old. The incidence of grade 3/4 AEs was higher for patients >= 65 years old than for those <65 years old in both the aflibercept (89.3% versus 80.5%) and placebo (67.4% versus 59.4%) arms. Interaction tests for grade 3/4 antiangiogenic agent-related AEs suggested no heterogeneity between the older and younger patient populations (p > 0.1). Conclusion: A limited but consistent benefit on both OS and PFS was associated with the addition of aflibercept to FOLFIRI compared with placebo in patients <65 and >= 65 years old, with a marked but manageable increase in the toxicity profile in older patients.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Geriatric Oncology
ISSN
1879-4068
e-ISSN
—
Volume of the periodical
9
Issue of the periodical within the volume
1
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
8
Pages from-to
32-39
UT code for WoS article
000422701400006
EID of the result in the Scopus database
2-s2.0-85028304694